Clinical Trial Update: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carfilzomib plus elotuzumab and dexamethasone for relapsed multiple myeloma after 1-3 prior treatments has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• carfilzomib + elotuzumab + dexamethasone

Snippet

Sponsor: Raija Silvennoinen | Conditions: Multiple Myeloma in Relapse | Phase 2 | Status: COMPLETED